Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas
<p>Abstract</p> <p>Background</p> <p>The function of promyelocytic leukemia (PML) bodies is not well known but plays an important role in controlling cell proliferation, apoptosis and senescence. This study was undertaken to analyze the clinical significance of PML body...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-11-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Online Access: | http://www.jeccr.com/content/27/1/73 |
| _version_ | 1819090493100785664 |
|---|---|
| author | Yasunaga Yuji Ishikawa Masataka Kubo Tadahiko Shimose Shoji Sugita Takashi Matsuo Toshihiro Ochi Mitsuo |
| author_facet | Yasunaga Yuji Ishikawa Masataka Kubo Tadahiko Shimose Shoji Sugita Takashi Matsuo Toshihiro Ochi Mitsuo |
| author_sort | Yasunaga Yuji |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The function of promyelocytic leukemia (PML) bodies is not well known but plays an important role in controlling cell proliferation, apoptosis and senescence. This study was undertaken to analyze the clinical significance of PML body expression in primary tumor samples from malignant fibrous histiocytoma (MFH) and liposarcoma patients.</p> <p>Methods</p> <p>We studied MFH and liposarcoma samples from 55 patients for PML bodies. Fluorescent immunostaining of PML bodies was performed in the paraffin-embedded tumor sections.</p> <p>Results</p> <p>PML body immunostaining was identified in 63.9% of MFH and 63.2% of liposarcoma samples. PML body expression rates of all sarcoma cells were 1.5 ± 1.8% (range: 0–7.0) in MFH and 1.3 ± 1.4% (0–5.2) in liposarcoma samples. PML body expression (p = 0.0053) and a high rate of PML body expression (p = 0.0012) were significantly greater prognostic risk factors for death than the other clinical factors in MFH patients. All liposarcoma patients without expression of PML were disease free at the end of the study.</p> <p>Conclusion</p> <p>Our study suggests that the presence of PML bodies may indicate a poor prognosis for MFH and liposarcoma patients.</p> |
| first_indexed | 2024-12-21T22:24:42Z |
| format | Article |
| id | doaj.art-2c94a4408c65403ab5c88a9f100c3326 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-12-21T22:24:42Z |
| publishDate | 2008-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-2c94a4408c65403ab5c88a9f100c33262022-12-21T18:48:15ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662008-11-012717310.1186/1756-9966-27-73Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomasYasunaga YujiIshikawa MasatakaKubo TadahikoShimose ShojiSugita TakashiMatsuo ToshihiroOchi Mitsuo<p>Abstract</p> <p>Background</p> <p>The function of promyelocytic leukemia (PML) bodies is not well known but plays an important role in controlling cell proliferation, apoptosis and senescence. This study was undertaken to analyze the clinical significance of PML body expression in primary tumor samples from malignant fibrous histiocytoma (MFH) and liposarcoma patients.</p> <p>Methods</p> <p>We studied MFH and liposarcoma samples from 55 patients for PML bodies. Fluorescent immunostaining of PML bodies was performed in the paraffin-embedded tumor sections.</p> <p>Results</p> <p>PML body immunostaining was identified in 63.9% of MFH and 63.2% of liposarcoma samples. PML body expression rates of all sarcoma cells were 1.5 ± 1.8% (range: 0–7.0) in MFH and 1.3 ± 1.4% (0–5.2) in liposarcoma samples. PML body expression (p = 0.0053) and a high rate of PML body expression (p = 0.0012) were significantly greater prognostic risk factors for death than the other clinical factors in MFH patients. All liposarcoma patients without expression of PML were disease free at the end of the study.</p> <p>Conclusion</p> <p>Our study suggests that the presence of PML bodies may indicate a poor prognosis for MFH and liposarcoma patients.</p>http://www.jeccr.com/content/27/1/73 |
| spellingShingle | Yasunaga Yuji Ishikawa Masataka Kubo Tadahiko Shimose Shoji Sugita Takashi Matsuo Toshihiro Ochi Mitsuo Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas Journal of Experimental & Clinical Cancer Research |
| title | Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas |
| title_full | Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas |
| title_fullStr | Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas |
| title_full_unstemmed | Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas |
| title_short | Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas |
| title_sort | immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas |
| url | http://www.jeccr.com/content/27/1/73 |
| work_keys_str_mv | AT yasunagayuji immunohistochemicalexpressionofpromyelocyticleukemiabodyinsofttissuesarcomas AT ishikawamasataka immunohistochemicalexpressionofpromyelocyticleukemiabodyinsofttissuesarcomas AT kubotadahiko immunohistochemicalexpressionofpromyelocyticleukemiabodyinsofttissuesarcomas AT shimoseshoji immunohistochemicalexpressionofpromyelocyticleukemiabodyinsofttissuesarcomas AT sugitatakashi immunohistochemicalexpressionofpromyelocyticleukemiabodyinsofttissuesarcomas AT matsuotoshihiro immunohistochemicalexpressionofpromyelocyticleukemiabodyinsofttissuesarcomas AT ochimitsuo immunohistochemicalexpressionofpromyelocyticleukemiabodyinsofttissuesarcomas |